Texas Biomedical Research Institute
Nonprofit biomedical research institute focused on infectious disease research, basic and translational science, and accelerated preclinical development. Operates high-containment laboratories and the Southwest National Primate Research Center to support animal models, vaccine and therapeutic testing, antibody discovery and technology translation through applied science and intellectual property.
Industries
Nr. of Employees
large (251-1000)
Patents
Cell culture media and methods for generating human alveolar macrophage-like cells
US-12173326-B2
View DetailsInvolucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
US-10751406-B2
View DetailsInvolucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
US-9730996-B2
View Details
Cell culture media and methods for generating human alveolar macrophage-like cells
US-12173326-B2
View DetailsInvolucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
US-10751406-B2
View DetailsInvolucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
US-9730996-B2
View DetailsProducts
Codon deoptimization software for genetic attenuation
A software tool that identifies nucleotide edits to reduce gene expression/function to assist design of attenuated strains for vaccine research; available for academic use with commercial licensing options.
Reverse genetics-based recombinant coronavirus vaccine constructs (patent applications)
Patent applications covering BAC-based replication-competent recombinant SARS-CoV-2 genomes and methods for making and using such constructs as bivalent live-attenuated vaccines.
Monoclonal antibody and neutralizing antibody patent applications
Patent filings describing human monoclonal antibodies and neutralizing antibodies against SARS-CoV-2 spike and related domains intended for therapeutic use.
Codon deoptimization software for genetic attenuation
A software tool that identifies nucleotide edits to reduce gene expression/function to assist design of attenuated strains for vaccine research; available for academic use with commercial licensing options.
Reverse genetics-based recombinant coronavirus vaccine constructs (patent applications)
Patent applications covering BAC-based replication-competent recombinant SARS-CoV-2 genomes and methods for making and using such constructs as bivalent live-attenuated vaccines.
Monoclonal antibody and neutralizing antibody patent applications
Patent filings describing human monoclonal antibodies and neutralizing antibodies against SARS-CoV-2 spike and related domains intended for therapeutic use.
Services
On-site execution of preclinical efficacy and safety studies for vaccines and therapeutics using multi-species animal models and high-containment facilities.
Licensing of patents and support for commercialization of research outputs, including antibody therapeutics, vaccine constructs and software tools.
Distribution of computational tools developed for research (e.g., codon deoptimization tool available for academic use) and support for adaptation to other organisms.
On-site execution of preclinical efficacy and safety studies for vaccines and therapeutics using multi-species animal models and high-containment facilities.
Licensing of patents and support for commercialization of research outputs, including antibody therapeutics, vaccine constructs and software tools.
Distribution of computational tools developed for research (e.g., codon deoptimization tool available for academic use) and support for adaptation to other organisms.
Expertise Areas
- Infectious disease research
- Vaccine development and live-attenuated vaccine design
- Monoclonal antibody discovery and therapeutic evaluation
- Preclinical animal model development and testing
Key Technologies
- High-containment (BSL-3/BSL-4) laboratory operations
- Nonhuman primate and humanized rodent models
- Reverse genetics and BAC-based recombinant viral genomes
- Codon deoptimization for genetic attenuation
News & Updates
Collaboration announced to advance a potential treatment for Marburg virus.
Agreement signed to enhance U.S. biodefense capabilities.
Participation in a global consortium to compare and prioritize therapeutic antibodies against SARS-CoV-2 using blinded, side-by-side in vivo testing; data contributed to a public database.
Article describing a software tool for codon deoptimization to attenuate genes and assist live-attenuated vaccine design; tool developed in collaboration with external bioinformatics groups and described in a peer-reviewed journal.
Renewal of a major grant supporting the institute's primate research center.
Recognition based on employee votes for workplace environment and culture; institute employs about 500 people on a 200-acre campus.
Collaboration announced to advance a potential treatment for Marburg virus.
Agreement signed to enhance U.S. biodefense capabilities.
Participation in a global consortium to compare and prioritize therapeutic antibodies against SARS-CoV-2 using blinded, side-by-side in vivo testing; data contributed to a public database.
Article describing a software tool for codon deoptimization to attenuate genes and assist live-attenuated vaccine design; tool developed in collaboration with external bioinformatics groups and described in a peer-reviewed journal.
Renewal of a major grant supporting the institute's primate research center.
Recognition based on employee votes for workplace environment and culture; institute employs about 500 people on a 200-acre campus.